Inceptionr LLC Purchases New Position in Glaukos Corporation $GKOS

Inceptionr LLC purchased a new stake in shares of Glaukos Corporation (NYSE:GKOS) in the first quarter, according to the company in its most recent filing with the SEC. The fund purchased 4,348 shares of the medical instruments supplier’s stock, valued at approximately $468,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in GKOS. First Horizon Corp lifted its holdings in shares of Glaukos by 1,715.4% in the fourth quarter. First Horizon Corp now owns 236 shares of the medical instruments supplier’s stock valued at $27,000 after purchasing an additional 223 shares in the last quarter. Los Angeles Capital Management LLC purchased a new position in shares of Glaukos during the fourth quarter valued at approximately $28,000. Larson Financial Group LLC grew its holdings in Glaukos by 62.0% during the fourth quarter. Larson Financial Group LLC now owns 345 shares of the medical instruments supplier’s stock worth $39,000 after buying an additional 132 shares in the last quarter. Parallel Advisors LLC grew its holdings in Glaukos by 159.2% during the first quarter. Parallel Advisors LLC now owns 368 shares of the medical instruments supplier’s stock worth $40,000 after buying an additional 226 shares in the last quarter. Finally, Farther Finance Advisors LLC raised its position in Glaukos by 111.4% in the 4th quarter. Farther Finance Advisors LLC now owns 408 shares of the medical instruments supplier’s stock valued at $46,000 after buying an additional 215 shares during the last quarter. 99.04% of the stock is owned by institutional investors.

Insider Transactions at Glaukos

In other Glaukos news, CFO Alex R. Thurman sold 10,000 shares of the company’s stock in a transaction dated Thursday, July 9th. The shares were sold at an average price of $155.00, for a total transaction of $1,550,000.00. Following the sale, the chief financial officer directly owned 43,681 shares of the company’s stock, valued at $6,770,555. This represents a 18.63% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Leana Wen sold 1,700 shares of the stock in a transaction dated Friday, May 1st. The stock was sold at an average price of $143.35, for a total transaction of $243,695.00. Following the transaction, the director owned 19,739 shares of the company’s stock, valued at $2,829,585.65. This represents a 7.93% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 61,273 shares of company stock valued at $8,882,003. 5.90% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

GKOS has been the topic of several recent analyst reports. BTIG Research restated a “buy” rating and set a $164.00 price objective on shares of Glaukos in a research note on Monday, July 13th. Truist Financial raised their price target on shares of Glaukos from $160.00 to $180.00 and gave the company a “buy” rating in a research report on Thursday, July 16th. Wall Street Zen cut shares of Glaukos from a “buy” rating to a “hold” rating in a report on Saturday, July 18th. Citigroup upped their price objective on shares of Glaukos from $162.00 to $175.00 and gave the stock a “buy” rating in a research report on Wednesday, July 8th. Finally, Wells Fargo & Company increased their price objective on shares of Glaukos from $135.00 to $138.00 and gave the company an “overweight” rating in a research note on Thursday, April 30th. Thirteen equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $154.85.

Glaukos Price Performance

Glaukos stock opened at $153.40 on Monday. The business’s 50 day simple moving average is $135.85 and its 200 day simple moving average is $123.52. Glaukos Corporation has a 12 month low of $73.16 and a 12 month high of $161.53. The company has a market cap of $9.01 billion, a price-to-earnings ratio of -46.77 and a beta of 0.75. The company has a current ratio of 5.43, a quick ratio of 4.73 and a debt-to-equity ratio of 0.10.

Glaukos (NYSE:GKOS) last issued its earnings results on Wednesday, April 29th. The medical instruments supplier reported ($0.18) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.30) by $0.12. Glaukos had a negative return on equity of 6.92% and a negative net margin of 34.34%.The firm had revenue of $150.57 million for the quarter, compared to analyst estimates of $137.00 million. During the same period in the previous year, the company posted ($0.22) earnings per share. The business’s revenue was up 41.2% on a year-over-year basis. Sell-side analysts forecast that Glaukos Corporation will post -0.57 EPS for the current year.

Glaukos Company Profile

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.